How Should Evidence be Assessed in Rare Diseases?

Name: How Should Evidence be Assessed in Rare Diseases?
Start: 2026-11-11T08:00
End: 2026-11-11T09:00
Location: Austria Center Vienna

ISPOR Europe 2026 · 11 November 2026 · 08:00–09:00

How Should Evidence be Assessed in Rare Diseases? was a session at ISPOR Europe 2026 on 11 November 2026 in Vienna, with 3 speakers on record.

Speakers

Sean Tunis — Speaker Tufts Center for the Evaluation of Value and Risk in Health
Karen Facey — Moderator Universities of Utrecht and Edinburgh and RWE4Decisions
J. Jaime Caro — Speaker McGill University; Thermo Fisher Scientific